Lovenox enoxaparin: Phase III data

In the open-label, international Phase III ATOLL trial in 910 patients, 0.5 mg/kg IV Lovenox administered prior

Read the full 170 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE